Asset Details
Do you wish to reserve the book?
A comprehensive overview of AL amyloidosis disease characteristics accumulated over two decades at a single referral center in Korea
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A comprehensive overview of AL amyloidosis disease characteristics accumulated over two decades at a single referral center in Korea
Do you wish to request the book?
A comprehensive overview of AL amyloidosis disease characteristics accumulated over two decades at a single referral center in Korea
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A comprehensive overview of AL amyloidosis disease characteristics accumulated over two decades at a single referral center in Korea
2023
Overview
Background
Characteristics of AL amyloidosis across Asia are not well-described in the literature. Thus, we overviewed the incidence and disease characteristics of AL amyloidosis in Korea.
Methods
We collected medical records of 302 AL amyloidosis patients and compared survival outcomes by predominant treatment strategy and at four time points: 1995–2003, 2004–2008, 2009–2013, and 2014–2018.
Results
The median age was 62 years (36–83). One hundred forty-one patients were classified as stage III (26.3%) or IV (47.9%). The patients diagnosed between 2014 and 2018 survived longer than those diagnosed at other time points due to the introduction of bortezomib (
p
< 0.01). In addition, patients who received upfront ASCT survived longer than those who received salvage ASCT or chemotherapy alone (
p
< 0.01). However, most of the 85 patients who experienced early death within 6 months were older than 75 years, had BMI less than 20, and had a high disease burden.
Conclusions
The incidence of AL amyloid has increased and survival outcomes have improved gradually, most likely due to introduction of novel agents and upfront ASCT. However, not all patients are suitable for these potent treatment modalities, and avoiding early death within 6 months remains a challenge.
Publisher
Springer Nature Singapore,Springer Nature B.V
We currently cannot retrieve any items related to this title. Kindly check back at a later time.